FDA 510(k)
FDA class 1
Substantially Equivalent
🇺🇸 United States
ACCESS HYBRITECH P2PSA QC ON THE ACCESS IMMUNOASSAY SYSTEMS
K Number: K112603
·
Decision Nov 4, 2011
Classifications
1
FEI Numbers
269
Registration Numbers
269
Same Product Code
492
Applicant Total
270
Review Days
58
Research this 510(k) in seconds
The Research Assistant summarizes clearance history, predicates and product-code trends — and cites every record.
Free to try · every answer cites its records
Basic Information
- Device Name
- ACCESS HYBRITECH P2PSA QC ON THE ACCESS IMMUNOASSAY SYSTEMS
- K Number
- K112603
- Device Class
- FDA class 1
- Clearance Type
- Abbreviated
- Regulation Number
- 862.1660
- Medical Specialty
- Clinical Chemistry
- Decision
- Substantially Equivalent
- Statement or Summary
- Summary
- Applicant
- Beckman Coulter, Inc.
- Date Received
- September 7, 2011
- Decision Date
- November 4, 2011
- Product Code
- JJX
- Advisory Committee
- Clinical Chemistry
- Review Advisory Committee
- IM
- Third Party
- N
Classifications
This FDA 510(k) entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| JJX | Single (Specified) Analyte Controls (Assayed And Unassayed) | FDA class 1 | Clinical Chemistry |
Similar 510(k) Clearances
Other 510(k) clearances with the same product code (JJX), ordered by most recent decision date.
Beta-CrossLaps CalCheck 5
FDA 510(k)
FDA Class 1
·Clinical Chemistry
Elecsys CYFRA 21-1 CalCheck 5
FDA 510(k)
FDA Class 1
·Clinical Chemistry
Multichem A1c
FDA 510(k)
FDA Class 1
·Clinical Chemistry
Audit MicroControls Linearity DROP LQ Blood Glucose
FDA 510(k)
FDA Class 1
·Clinical Chemistry
LIAISON CMV IgM Serum Control Set
FDA 510(k)
FDA Class 1
·Clinical Chemistry
LIAISON EBV IgM Serum Control Set
FDA 510(k)
FDA Class 1
·Clinical Chemistry
Other Clearances by Beckman Coulter, Inc.
| K Number | Device Name | ||
|---|---|---|---|
| K252169 | Access BNP II | Mar 24, 2026 | Substantially Equivalent |
| K254059 | Access anti-HBc IgM | Mar 13, 2026 | Substantially Equivalent |
| K253687 | Access anti-HBc Total | Feb 19, 2026 | Substantially Equivalent |
| K251995 | Access anti-HAV IgM | Jan 27, 2026 | Substantially Equivalent |
| K250588 | Access Rubella IgG | Nov 17, 2025 | Substantially Equivalent |
| K252580 | iQ200 Series | Sep 10, 2025 | Substantially Equivalent |
| K243846 | Access anti-HAV | Sep 9, 2025 | Substantially Equivalent |
| K243804 | MicroScan Dried Gram-Negative MIC/Combo Panels with Cefepime (CPE) (0.12-64 µg/mL) (MicroScan) | Aug 20, 2025 | Substantially Equivalent |
| K250036 | MicroScan Dried Gram-Positive MIC/Combo Panels with Daptomycin (DAP) (0.06-32 µg/mL) | Aug 15, 2025 | Substantially Equivalent |
| K243483 | Access hsTnI | Aug 1, 2025 | Substantially Equivalent |